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Abstract: Introduction: Warthin’s tumor, also known as papillary cystadenoma lymphomatosum, monomorphic adenoma, or adenolymphoma, is a
benign cystic tumor of the salivary glands containing abundant lymphocytes and lymph node-like stroma. It is named after the pathologist Aldred
Scott Warthin, who described two cases in 1929.Objective: The aim of this study is to analyze the pathogenesis of Warthin’s tumor.Methods:A total of
15 patients with Warthin’s tumor were studied. Hematoxylin and eosin stains, which have been used for at least a century and are still essential for
recognizing various tissue types and the morphologic changes for cancer diagnosis, were used. Warthin’s tumor was evaluated for the expression of
MGMT, CD3, HSP90AA1, MMP-1, Bcl-2, CD79A, IgG, Ki-67, p53, IgM, OPN, S100, myeloperoxidase, and VEGF by immunohistochemistry.
Results: Immunohistochemical staining confirmed that the immune cells within the follicles of Warthin’s tumor were positive for MGMT (10.0 ±
0.34%), Ki-67 (13.3 ± 0.45%), Bcl-2 (42.6 ± 8.33), and p53 (11.6 ± 2.3). The immune cells associated with CD3 were present at the stroma of
residual cells (47.3 ± 3.89); however, they were not present in the epithelium cell layers. B cells (CD79A) consistent with germinal centers were
present within the immune cells and formed follicles (43.2 ± 13.5%). Conclusions:Histopathological analysis of the stroma and parenchyma revealed
balanced distribution of epithelial and stromal component. Epithelial component of the Warthin’s tumor is the trigger for the tumor process. This
study indicates that the Warthin tumor is a consequence of inflammatory etiology.
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Introduction
History
Papillary cyst adenolymphoma is the second most com-
mon benign cystic tumor of the salivary gland. This tumor
was first described by Hilderbrand in 1895 as a form of
congenital cyst of the neck. Historically, Hilderbrand’s
description was forgotten. In 1929, Warthin called this
tumor as papillary cystadenoma lymphomatosum. Cur-
rently, this tumor is called as adenolymphoma, Warthin’s
tumor, and cystic papillary adenoma [1].
Clinical features
Warthin’s tumors occur almost exclusively in the parotid
glands, in its superficial lobe and rarely in the deeper lobe
(10%). It presents as a slow growing node, firm or
fluctuant at palpation, with indolent mass, multicentric
(12%–20%), and bilateral (5%–14%) [2]. Ellis and Auclair,
[3], has shown adenolymphoma incidence between 5%
and 11% of all parotid gland tumors, and Eveson and
Cawson, [4] has found 14%–30% of parotid tumors.
Etiology
There is no consensus regarding the origin of this tumor.
However, the studies by Kotwall [5], Pinkston and Cole
[6], and Yoo et al. [7] have demonstrated that these
tumors are associated with cigarette smoking, which may
be due to the irritation of the ductal epithelium by
tobacco smoke that initiates the tumorigenesis.
Studies conducted among atomic bomb survivors
suggest that radiation may also be implicated in the
Warthin’s tumorigenesis [8]. There is also an earlier view
by Santucci et al. [9] of the strong association of the
Epstein–Barr virus in the etiology of Warthin’s tumors.
Papillary cystadenoma lymphomatosum (Warthin’s
tumor) is generally considered to be a benign tumor.
However, only a few well-documented cases of malignant
transformation have been reported [10].
Histogenesis
Warthin’s tumor has incomprehensible histogenesis of
lymphoid stroma [11]. According to the 2005 World
Health Organization classification of tumors, Warthin’s
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tumor can be defined as a tumor composed of glandular
and often cystic structures, sometimes with a papillary
cystic arrangement, lined with characteristic bilayered
epithelium, comprising inner columnar eosinophilic or
oncocytic cells surrounded by smaller basal cells.
Lymphoid stroma often contains many germ centers,
which may be the result of an immune response to
neoplastic epithelium or may represent residual lymphoid
tissue in the lymph nodes partially replaced by neoplastic
epithelium [12]. van der Wal et al. [13] have shown that
the lymph nodes near the gland may be present within the
healthy tissue of salivary gland, and on the other hand,
salivary gland tissue may be present in the structure of
lymph nodes.
Expression of markers
Immunostain reactions for CD20cy and CD45RO in 21
cases with Warthin’s tumor revealed a predominance of B
lymphocytes specifically marked with CD20cy in five
cases (23.8%) and T lymphocytes marked with CD45RO
in four cases (19%) [14].
Studies by Barnes et al. [12, 15] have shown B
(CD20), NK (CD56), and T (CD3) cells, including
helper (CD4) and suppressor (CD8) subtypes, in
Warthin’s tumors lymphocyte population. The lympho-
cyte population is polyclonal, with a predominance of
IgA-producing cells. CD9 has been reported to be pres-
ent in every Warthin’s tumor (18/18) [16].
Bcl-2 also plays a role in the development of adenomas
[17]. Occult B-cell monoclonality as determined by
IgH FISH/PCR and Bcl-2 FISH/PCR was not identi-
fied in the selected random cases of Warthin’s tumor and
did not establish the benign polyclonal nature of the
lymphoid stroma in this neoplasm [18]. Results from the
Genetzakis et al. [19] study suggest that Bcl-2 can be
used to identify locally advanced or histologically aggres-
sive tumors with a higher survival probability following
the standard treatment modalities.
The epithelial malignancy was labeled with cytokeratin
(CK) and epithelial membrane antigen (EMA). The
immunohistochemical study of the bilayer epithelial com-
ponent of Warthin’s tumor has different immunostaining
pattern of the two types of epithelia. CKs and EMA are
the two most widely used markers (CK and EMA immu-
nostain) for epithelial origin cells, and they usually do not
show up in the Warthin’s tumor after the malignant
transformation [2].
In all the Warthin’s tumor cases, the immunostaining
for CK5/6 was positive in bilayer epithelial basal cells,
both in the structure of the cysts and the papillae.
In the case of the immunostaining for p63, Dăguci
et al. [20] noticed limited nuclear positivity in the basal
cells, while the columnar cells’ nucleus were negative.
By reverse transcriptase and nested PCR, all tumors
expressed p63 [21]. Neoplastic epithelial cells of Warthin’s
tumor showed slightly positive staining for S100 alpha in
their cytoplasm, and there was a strong positive reaction
in a limited number of lymphoid stroma [22].
Beta4-integrin is strongly expressed in all cell basement
membrane and intercellular contacts of the epithelium.
E-cadherin and desmoglein-2 are expressed in cell–cell
contacts, but not in basal cell–basement membrane
connections.
HCAM (CD44s) is expressed in intercellular contacts
of both luminal basal cells and monocytic–lymphocytic
stroma. ICAM-1 has weak expression in both luminal and
basal epithelial cells and strong expression in the germinal
lymphocytic centers. CAM is expressed in the ductal
structure of bilayer secretory in the neoplastic epithelium
of Warthin’s tumor [23].
Wang et al. [24] have shown that PRDM1 is expressed
only on the epithelial component but not on ectopic
lymphoid tissue of the Warthin’s tumor. IgG4 levels
increased in 27% of Warthin’s tumors [25], and
35.71% of Warthin’s tumors expressed VEGF [26].
The etiology of Warthin’s tumor is still not clearly
investigated. In this study, we tried to evaluate some
immunostaining marker expressions, focusing on the
lymphocyte and epithelial population that were present
in Warthin’s tumor. The aim of this study is to find
markers that can help understand the pathomechanism
of Warthin’s tumor.
Methods
Benign tumor of the salivary gland was used as the study
material. Only patients with Warthin’s tumor, who had
undergone surgery during 2013–2015 in the Depart-
ment of Oral and Maxillofacial Surgery of the Sumy
Regional Hospital, took part in this study. A total of
15 patients with Warthin’s tumor were included, and the
Warthin’s tumor without malignant metastasis was inves-
tigated. Hematoxylin and eosin staining, which have been
used for at least a century and are still essential for
recognizing various tissue types and the morphologic
changes for cancer diagnosis, was performed.
Immunostaining for proteins was performed on
formalin-fixed (pH 7.4), paraffin-embedded Warthin’s
tumor tissue sections using mouse monoclonal antibody
(Table I). Based on the manufacturer guidelines (Thermo
Fisher Scientific), immunohistochemistry protocol was
carried out [27].
Briefly, 4-μm thick tissue sections were dewaxed in
xylene and were brought to water through graded alco-
hols. Antigen retrieval was performed by microwaving
slides in 10 mM citrate buffer (pH 6.2) for 30min at high
power, according to the manufacturer’s instructions.
To remove the endogenous peroxidase activity, sec-
tions were then treated with freshly prepared 1.0%
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hydrogen peroxide in the dark for 30 min at 37 °C.
Nonspecific antibody binding was blocked using blocking
serum. Sections were then incubated for 30min at 37 °C,
with the primary antibodies against protein diluted in
phosphate-buffered saline (pH 7.2), by triple washing
with PBS.
Anti-mouse IgG–horseradish peroxidase conjugate
(1:40,000 dilution) was used for the detection of the
primary antibodies. Then, the sections were incubated for
20min at 37 °C and visualized by reacting with DAB
(3,3’-diaminobenzidine).
The appearance of the positive factors was detected
semiquantitatively by counting the intensity of positive
staining in the visual field. Proteins in cytoplasmic region
were determined by the intensity of DAB staining: 0, no;
0.25, weak; 0.5, average; 0.75, strong; and 1, very
strong. Proteins in nucleus were determined by counting
DAB-positive nuclei.
The data were analyzed using STATISTICA 8.0
(version STA862D175437Q), and the results were pre-
sented as mean (± SD). Cluster analysis was also carried
out using STATISTICA 8.0.
Results
Warthin’s tumor is sharply demarcated with a thin
capsule. At the periphery of the lesions, there is extensive
fibrosis, with dense hypocellular collagen and myofibro-
blastic spindle cell proliferation. There is a heavy mixed
inflammatory infiltrate (Fig. 1D) composed of chronic
inflammatory cells and sheets of macrophages.
The epithelium includes dual layers of cells: one layer
shows the oncocytic luminal cells (Fig. 1A) with high and
columnar structure and the other layer shows palisading
of their bland single ovoid nuclei. Deep to this layer, lie
smaller flattened or cuboidal basal cells (Fig. 1C). Their
cytoplasm is similar, but less profuse. No significant
nuclear atypical or mitotic activity is recognized. Small
foci of squamous metaplasia, scanty goblet cells, and very
occasional sebaceous cells are seen.
The stroma comprises lymphoid tissue displaying vary-
ing degrees of reactivity, and germinal centers are normal.
Increased numbers of mast cells and plasma cells may
also be seen. The cystic spaces comprise eosinophilic
Table I Types of antibody dilution, clone, and level of the protein expression in Warthin’s tumor
Epithelium
S. No Antibody Dilute Clone Oncocytic cells (%) Basal cells (%) Lymphoid tissue (%)
1 MGMT 1:50 MT 3.1 25.6 ± 0.59 59.3 ± 1.79 10.0 ± 0.34
2 CD3 1:150 SP7 – – 47.3 ± 3.89
3 HSP90AA1 1:200 Poliklon 0.5 ± 0.15 0.41 ± 0.23 0.5 ± 0.26
4 MMP-1 1:50 Poliklon 0.41 ± 0.23 0.5 ± 0.15 0.36 ± 0.26
5 Bcl-2 1:100 100/D5 – 0.15 ± 0.03 42.6 ± 8.33
6 CD79A 1:200 SP18 – – 43.2 ± 13.5
7 IgG 1:500 Poliklon 0.08 ± 0.05 0.08 ± 0.06 0.75 ± 0.15
8 Ki-67 1:100 SP6 – 30.0 ± 1.5 13.3 ± 0.45
9 p53 1:100 SP5 – 3.6 ± 2.3 11.6 ± 2.3
10 IgM 1:500 Poliklon – – 0.50 ± 0.15
11 OPN 1:100 Poliklon 0.66 ± 0.12 0.41 ± 0.32 –
12 S100 1:100 4C4.9 – – 21.6 ± 8.2
13 Myeloperoxidase 1:100 Poliklon – – –
14 VEGF 1:200 Poliklon 0.33 ± 0.15 0.50 ± 0.15 –
15 Glycophorin 1:100 Poliklon – – 5.6 ± 1.13
16 Chromogranin A 1:100 Poliklon 0.25 ± 0.12 0.41 ± 0.22 0.5 ± 0.15
Fig. 1. Warthin tumor stained by hematoxylin and eosin. Magnifi-
cation 150×. A – the oncocytic cells; B – the cystic spaces;
C – the cuboidal basal cells; D – the mixed inflammatory
infiltration
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secretions with occasional crystal formation and laminat-
ed figures resembling corpora amylacea (Fig. 1B). Atypi-
cal cells can be projected with several mitotic figures, but
none is abnormal.
Immunohistochemical staining of the immune cells
within the follicles of Warthin’s tumor were positive for
MGMT, Ki-67, Bcl-2, and p53 (Fig. 2).
The immune cells were associated with a CD3+
residual cell meshwork (Fig. 2), but they were not
present in the epithelium cells. Some CD79A-B cells
consistent with germinal centers were present within
the immune cells. B cells formed follicles (Fig. 2R), and
the inflammatory infiltrate expressed IgG and IgM.
Immunostaining performed on IgG showed diffuse ex-
pression. IgM was product of B cells-CD79A forming
follicles (Fig. 2P).
The inflammatory infiltrate was positive for S100 and
negative for epithelial cells (Fig. 2I). S100-positive
immune cells had subepithelial localization. MMP-1 and
OPN presence was negative in the immune cells of
Warthin’s tumor (Fig. 2), but weakly positive for
HSP90AA1 (Fig. 2N). Epithelium in the oncocytic lu-
minal cells and basal cells areas expressed OPN and
MMP-1 (Fig. 2L, O), respectively. Warthin’s tumor was
negative for myeloperoxidase (Fig. 3).
Chromogranin A (Fig. 4A, B) and glycophorin
expression in Warthin’s tumor are shown in Fig. 4.
Glycophorin expression was negative for epithelial cells.
Glycophorin stains small areas of hemorrhage in the
stroma of tumor. Warthin’s tumor was positive for chro-
mogranin A (Fig. 4A, B). Epithelium and immune cells
Fig. 3. Myeloperoxidase, negative expression in Warthin’s tumor.
Magnification 400×. A – negative expression in the onco-
cytic cells; B – negative expression in the cuboidal basal
cells; C – negative expression in the mixed inflammatory
infiltration
Fig. 4. Chromogranin A, VEGF, and glycophorin expression in
Warthin’s tumor. Magnification 400×
Fig. 2. Marker expressions in Warthin’s tumor. Magnification
400×
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expressed chromogranin A. Oncocytic luminal and basal
cell areas expressed VEGF (Fig. 4C). Different levels of
the marker expressions were shown in Table I.
Cluster analysis combining a large number of para-
meters obtained from the analysis was disseminated on
two objects, G and M clusters, so that each object G
includes subclusters. Results from the cluster analysis of
protein expression are shown in Fig. 5.
The horizontal axis represents proteins and the vertical
axis represents the connection between the proteins. The
first stage of the tumor–protein relationship was connec-
tion of the following proteins: HSP90AA1 in basal cells,
CD3 and glycophorin in mixed inflammatory infiltrate,
VEGF and Ki-67, IgG in basal cells.
The indicated proteins in oncocytic luminal cells have
minimum distance and are characterized by epithelium,
including dual layer stimulus on inflammatory infiltrate
(Fig. 5, black line). The indicators are part of the second
cluster that shows the influence of stroma in tumor
epithelial component (Fig. 5, gray line).
Discussion
We have shown that expression of p53 may be associated
with the regulation of MGMT expression in Warthin’s
tumors. Levels of MGMT and low level of p53 are
predictors of Warthin’s tumors.
Rolhion et al. [28] reported that MGMT gene expres-
sion was significantly lower in p53 benign tumors, and
mutant p53 was clearly correlated with poor survival in
tumor. Some of these tumors, such as those derived from
the brain, lung, head and neck, and lymphomas, also have
hypermethylation-associated inactivation of MGMT.
The Bcl-2 protein is a potent inhibitor of cell death,
whereas the wild-type p53 protein activates the apoptotic
pathway [29].
Mutated p53 loses this function and allows the prolif-
eration of neoplastic cells. Bcl-2 also modulates the
function of p53 and triggers cell proliferation and trans-
formation [30]. We defined that manifestation of Bcl-2 in
inflammatory infiltrate of Warthin’s tumor showed good
prognostic markers.
Expression of the Ki-67 proliferation marker, which
detects all phases of the cell cycle except G0, is known to
predict disease outcome in many human malignancies
[31]. At the same time, Ki-67 and p53 were reported to
be used in a parallel manner [32].
The positivity for Ki-67 on the basal layer may be
explained by the presence of active proliferating cysts.
Generally, the positive expression of Ki-67 in the cells of
basal layer may indicate the grade of epithelial prolifera-
tion. Immunohistochemical expression of the proteins
p53, Bcl-2, and Ki-67 in the Warthin’s tumor may indi-
cate the growth aspect of the proliferating epithelium and
immune cells.
The expression of S100 has been detected as proin-
flammatory phagocytes cells at sites of intestinal
inflammation [33, 34]. Systemic autoimmune diseases
(dermatomyositis, systemic lupus erythematosus, Kawasaki
disease, etc.) are associated with S100 expression of macro-
phages infiltrating with degeneration of tissue [35, 36].
Macrophages are versatile cells that play many roles.
Along with dendritic cells, they are foremost among the
cells that present antigens, and their crucial role is to
initiate immune response. As secretory cells, monocytes
Fig. 5. Diagram of cluster analysis
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and macrophages are vital to the regulation of immune
responses and the development of inflammation [37]. We
have supposed that the macrophages act as antigen-
presenting cells in the Warthin’s tumor: they activate
helper T cells (CD3) and B cells (CD79A) by presenting
them with antigens.
The question is: What is the antigen in the Warthin’s
tumor? We can offer a couple of options for the antigen:
(a) epithelial cells infected by a virus or chemical such as
tobacco smoke, and as a result of it, there is a mutation
and immune response and (b) autoimmune response on
its own duct cells.
IgG and IgM are basic antibodies that are produced by
B cells. They act as antibodies through several mechan-
isms: IgG-mediated binding of pathogens causes their
immobilization and binding together via agglutination,
IgG coating of pathogen surfaces (known as opsoniza-
tion) allows their recognition and ingestion by phagocytic
immune cells, IgG activates the classical pathway of the
complement system, a cascade of immune protein pro-
duction that results in pathogen elimination, and IgG also
binds and neutralizes toxins.
Because IgM is a large molecule, it cannot diffuse well
and is found in the interstitium only in very low quanti-
ties. Due to its polymeric nature, IgM possesses high
avidity and is particularly effective at complex activation.
By itself, IgM is an ineffective opsonin; however, it
contributes greatly to the opsonization by activating
complement and causing C3b to bind to the antigen.
C3b is the larger of two elements formed by the
cleavage of complement component 3. C3b covalently
bonds to microbial cell surfaces within an organism’s
body. This leads to the production of surface-bound
C3-convertase and accordingly more C3b components.
Bound C3b also aids in the opsonization of the microbe
by macrophages [38].
The measurement of IgG can be a diagnostic tool for
certain conditions, such as autoimmune diseases. Clini-
cally, measured IgG antibody levels are generally consid-
ered to be indicative of an individual’s immune status to
particular pathogens. A common example of this practice
are titers drawn to demonstrate serologic immunity to
measles, mumps, and rubella, hepatitis B virus, and vari-
cella, among others [39]. We obtained a strong reaction
of IgG, and the above confirms our view of the viral
etiology in the Warthin’s tumor.
The other protein expression that confirms the viral
etiology in the Warthin’s tumor is the nonexpression of
myeloperoxidase. Myeloperoxidase and glycophorin are
expressed in neutrophils [40, 41], which are mainly
present in inflammation caused by bacteria.
The chemoattractant property of OPN has been
demonstrated in the migration of monocytic cells/
macrophages, T cells, smooth muscle cells, endothelial
cells, epithelial cells, and several malignant cells [42–44].
In addition, OPN is an important factor in immune
system activation and virus resistance and was named by
Patarca et al. [45] in 1989 as T-lymphocyte activation 1
protein (Eta-1). Today, this protein is designated as OPN
and is known to be involved in wound repair, immune
function, angiogenesis, and cell survival.
Both soluble OPN, which works as a cytokine, and
immobilized OPN, which functions as an extracellular
matrix protein, protect against apoptosis and induce
survival and proliferation in several cell types. OPN has
a prosurvival and/or proliferative function in adherent
cell types, such as smooth muscle cells [46] and epithelial
cells [47].
Fig. 6. Pathogenesis of Warthin’s tumor
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Our results suggest that as one of the most abundant
proteins in tumor cells and a key factor that stabilizes
tumor proteins involved in tumor growth and survival,
increased HSP90 expression may play an important
role in stimulating development of Warthin’s tumor.
In neoplasia, HSPs have been associated in multidrug
resistance [48] and regulation of apoptosis [49], as well as
modulators of p53 function [50]. Conversely, wild-type
(but not mutant) p53 downregulates HSP90 expression
[51].
Our data indicated that MMP-1 reduced cell prolifer-
ation, as demonstrated by the low Ki-67 expression in
tumors epithelium. Probably, as a consequence of this,
Warthin’s tumor has also slow growth and reduction of
collagen-1.
On the contrary, overexpression of MMP-1 (in con-
junction with other genes) in human breast carcinoma
cells increased xenograft growth rates [52] and facilitated
the assembly of new tumor blood vessels that causes
release of tumor cells into the circulation and the breach-
ing of lung capillaries by circulating tumor cells to seed
pulmonary metastasis.
Based on the results of the cluster analysis and studies
of scientists, form of proteins rapport was established
(Fig. 6).
Conclusions
1. Histopathological analysis of the stroma and paren-
chyma revealed balanced distribution of epithelial and
stromal component. Epithelial component of the
Warthin’s tumor is the trigger for the tumor process.
Reactive proliferation was present as a response to
epithelial proliferation that modulates it, which caused
active production of IgG and IgM. Epithelium pro-
liferation also stimulated macrophage and T-cell
infiltration.
2. Markers of this study showed inflammatory
etymology of Warthin’s tumor. The immunostaining
of stromal component with Ki-67 markers showed
lymphocytic proliferation in the stromal cells of the
tumor with predominantly type B-plasmacytoid
(CD79A immunostained). This study indicates that
Warthin’s tumor is a consequence of inflammatory
etiology.
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